Boston Scientific Assessed $431M in Patent Suit

A Texas jury found against Natick, MA-based Boston Scientific (NYSE: BSX) in a patent infringement suit involving drug-eluting stent products, awarding $431 million in damages to its opponent, the company announced today. The verdict, from a U.S. District Court jury in Marshall, Texas, found that the firm’s Taxus Express and Taxus Liberte stent products infringe a patent held by Dr. Bruce Saffran, and that Saffran’s patent is valid, the company reported in a statement. Boston Scientific said it would seek to overturn the verdict, and, if unsuccessful, that it would appeal the decision.

Bob is Xconomy's founder and chairman. You can email him at bbuderi@xconomy.com. Follow @bbuderi

Trending on Xconomy